Payment overview · 2025
General Payments
$533.62
32 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Ryan Looney, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · STARKVILLE, MS · NPI 1568807196
Verified facts
What the public records show
CMS Open Payments records show Robert Ryan Looney, D.O. received $533.62 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.84 | 39.1% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.18 | 16.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.16 | 16.0% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.40 | 8.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.79 | 6.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.68 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.92 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.65 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $533.62 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.59 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.91 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.16 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.34 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.45 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.40 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $32.98 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.98 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.68 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 58 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 186 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
186 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 345 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 304 | 110 |
| Losartan Potassium | Losartan Potassium | 197 | 64 |
| Ozempic | Semaglutide | 186 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 59 |
| Metformin Hcl | Metformin Hcl | 155 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 37 |
| Omeprazole | Omeprazole | 132 | 43 |
| Carvedilol | Carvedilol | 124 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 43 |
| Lisinopril | Lisinopril | 119 | 45 |
| Potassium Chloride | Potassium Chloride | 116 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 41 |
| Montelukast Sodium | Montelukast Sodium | 99 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 32 |
| Famotidine | Famotidine | 84 | 29 |
| Farxiga | Dapagliflozin Propanediol | 83 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 19 |
| Allopurinol | Allopurinol | 74 | 22 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 27 |
| Furosemide | Furosemide | 66 | 34 |
| Simvastatin | Simvastatin | 65 | 24 |
| Gabapentin | Gabapentin | 62 | 19 |
| Celecoxib | Celecoxib | 61 | 18 |
| Eliquis | Apixaban | 58 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 18 |
| Spironolactone | Spironolactone | 53 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 13 |
| Jardiance | Empagliflozin | 51 | 17 |
| Buspirone Hcl | Buspirone Hcl | 50 | 17 |
| Mupirocin | Mupirocin | 49 | 28 |
| Meloxicam | Meloxicam | 46 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 38 |
| Trazodone Hcl | Trazodone Hcl | 44 | 16 |
| Metformin Hcl Er | Metformin Hcl | 42 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 15 |
| Azelastine Hcl | Azelastine Hcl | 41 | 22 |
| Linzess | Linaclotide | 41 | 13 |
| Bupropion Xl | Bupropion Hcl | 38 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Valsartan | Valsartan | 31 | 11 |
| Atenolol | Atenolol | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Nystatin | Nystatin | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | 11 |
| Chlorthalidone | Chlorthalidone | 25 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 12 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 16 |
| Prednisone | Prednisone | 24 | 11 |
| Ramipril | Ramipril | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | 11 |
| Glimepiride | Glimepiride | 23 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | 11 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $533.62 · 32 records | ABBVIE INC. | AREXVY, CREON, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, LINZESS, NURTEC ODT, OFEV, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error